If a drugmaker could cut coupons, Eli Lilly would be doing so. Because of “the business challenges the company faces,” this year many of its top staffers and executives will not be receiving their usual annual boosts to base salaries, according to a filing made late last week with the US Securities and Exchange Commission.

It’s been a rough couple of years for Eli Lilly. In August 2010, the drugmaker had to end a phase 3 clinical trial of their Alzheimer’s drug semagacestat after it actually made symptoms worse. And while Pfizer has been getting a lot of attention for losing its patent on Lipitor (avortistatin), Lilly’s patent on antipsychotic Zyprexa (olanzapine) expired in November and in just two months, sales fell 44 percent.

Chief executive John Lechleiter has frozen his own pay at $1.5 million each year for the last three years, which is already remarkably...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?